Current Developments and Innovations in Early Detection and Subsequent Treatment of Cancer
DOI:
https://doi.org/10.30683/1929-2279.2024.13.12Keywords:
Oncology, radiopharmaceuticals, immunotherapy, personalised medicine, genetic testing, biomarkersAbstract
Objective: The study aimed to identify key trends in modern oncology by analysing developments and innovations in early cancer diagnosis and treatment methods. Using a comparative analysis of scientific and healthcare systems in Albania, Bulgaria, Kyrgyzstan, and Uzbekistan, the study examined innovative diagnostic approaches such as liquid biopsy, biomarker discovery, genetic testing, advanced imaging techniques, and artificial intelligence algorithms.
Methods: For treatment, it highlighted immunotherapy, personalised medicine, cellular, targeted, and combination therapies, as well as the development of radiopharmaceuticals and 3D modelling for surgical planning.
Results: Key findings revealed that the lack of economic support for research is the primary barrier to innovation in all four countries. Bulgaria, benefiting from European Union membership, demonstrated the highest potential for advancing oncology due to its stronger scientific, technical, regulatory, and social indicators. In contrast, Albania's transition economy and Kyrgyzstan’s social and geographical challenges significantly hinder progress. The findings underline the need for enhanced economic investment, international cooperation, and regulatory support to address disparities and foster the implementation of innovative oncology practices globally.
Conclusion: This regional analysis provides insights into how tailored approaches can bridge the gap between low- and high-income countries in advancing cancer care.
References
Zub V, Kotuza A, Tolstanov O. Communication of oncological patients with oncologists: main problems and problem-solving strategies. International Journal of Medicine and Medical Research 2022; 8(2): 74-82. https://doi.org/10.11603/ijmmr.2413-6077.2022.2.13594 DOI: https://doi.org/10.11603/ijmmr.2413-6077.2022.2.13594
Battaglia TW, Mimpen IL, Traets JJ, van Hoeck A, Zeverijn LJ, Geurts BS, de Wit GF, Noë M, Hofland I, Vos JL, Cornelissen S, Alkemade M, Broeks A, Zuur CL, Cuppen E, Wessels L, van de Haar J, Voest E. A pan-cancer analysis of the microbiome in metastatic cancer. Cell 2024; 187(9): 2324-2335. https://doi.org/10.1016/j.cell.2024.03.021 DOI: https://doi.org/10.1016/j.cell.2024.03.021
Tsimberidou AM, Fountzilas E, Nikanjam M, Kurzrock R. Review of precision cancer medicine: Evolution of the treatment paradigm. Cancer Treatment Reviews 2020; 86: article 102019. https://doi.org/10.1016/j.ctrv.2020.102019 DOI: https://doi.org/10.1016/j.ctrv.2020.102019
Pich O, Bailey C, Watkins TB, Zaccaria S, Jamal-Hanjani M, Swanton C. The translational challenges of precision oncology. Cancer Cell 2022; 40(5): 458-478. https://doi.org/10.1016/j.ccell.2022.04.002 DOI: https://doi.org/10.1016/j.ccell.2022.04.002
Senga SS, Grose RP. Hallmarks of cancer - The new testament. Open Biology 2021; 11: article 200358. https://doi.org/10.1098/rsob.200358 DOI: https://doi.org/10.1098/rsob.200358
Hanahan D. Hallmarks of cancer: New dimensions. Cancer Discovery 2022; 12(1): 31-46. https://doi.org/10.1158/2159-8290.CD-21-1059 DOI: https://doi.org/10.1158/2159-8290.CD-21-1059
Gohil SH, Iorgulescu JB, Braun DA, Keskin DB, Livak KJ. Applying high-dimensional single-cell technologies to the analysis of cancer immunotherapy. Nature Reviews Clinical Oncology 2021; 18(4): 244-256. https://doi.org/10.1038/s41571-020-00449-x DOI: https://doi.org/10.1038/s41571-020-00449-x
Weeden CE, Hill W, Lim EL, Grönroos E, Swanton C. Impact of risk factors on early cancer evolution. Cell 2023; 186(8): 1541-1563. https://doi.org/10.1016/j.cell.2023.03.013 DOI: https://doi.org/10.1016/j.cell.2023.03.013
He X, Liu X, Zuo F, Shi H, Jing J. Artificial intelligence-based multi-omics analysis fuels cancer precision medicine. Seminars in Cancer Biology 2023; 88: 187-200. https://doi.org/10.1016/j.semcancer.2022.12.009 DOI: https://doi.org/10.1016/j.semcancer.2022.12.009
International Agency for Research on Cancer. World 2022. https://gco.iarc.who.int/media/globocan/factsheets/populations/900-world-fact-sheet.pdf
International Agency for Research on Cancer. 2022. WHO Europe region (EURO). https://gco.iarc.who.int/media/ globocan/factsheets/populations/994-who-europe-euro-fact-sheet.pdf
International Agency for Research on Cancer. Northern Africa, Central and Western Asia hub 2022. https://gco. iarc.who.int/media/globocan/factsheets/populations/975-northern-africa-central-and-western-asia-hub-fact-sheet.pdf
International Agency for Research on Cancer. Albania 2022. https://gco.iarc.who.int/media/globocan/factsheets/populations/8-albania-fact-sheet.pdf
International Agency for Research on Cancer. Bulgaria 2022. https://gco.iarc.who.int/media/globocan/factsheets/populations/100-bulgaria-fact-sheet.pdf
International Agency for Research on Cancer. Kyrgyzstan 2022. https://gco.iarc.who.int/media/globocan/factsheets/ populations/417-kyrgyzstan-fact-sheet.pdf
International Agency for Research on Cancer. Uzbekistan 2022. https://gco.iarc.who.int/media/globocan/factsheets/ populations/860-uzbekistan-fact-sheet.pdf
World Health Organization. Health data overview for the Republic of Albania 2022. https://data.who.int/countries/008
World Health Organization. Health data overview for the Republic of Bulgaria 2022. https://data.who.int/countries/100
World Health Organization. Health data overview for the Kyrgyz Republic 2022. https://data.who.int/countries/417
World Health Organization. Health data overview for the Republic of Uzbekistan 2022. https://data.who.int/countries/ 860
Nikanjam M, Kato S, Kurzrock R. Liquid biopsy: Current technology and clinical applications. Journal of Hematology & Oncology 2022; 15: article 131. https://doi.org/10.1186/s13045-022-01351-y DOI: https://doi.org/10.1186/s13045-022-01351-y
Woitek R, Gallagher FA. The use of hyperpolarised 13C-MRI in clinical body imaging to probe cancer metabolism. British Journal of Cancer 2021; 124(7): 1187-1198. https://doi.org/10.1038/s41416-020-01224-6 DOI: https://doi.org/10.1038/s41416-020-01224-6
Eraj S, Sher DJ. PET/CT: Radiation therapy planning in head and neck cancer. PET Clinics 2022; 17(2): 297-305. https://doi.org/10.1016/j.cpet.2021.12.007 DOI: https://doi.org/10.1016/j.cpet.2021.12.007
Zhang G, Ye HR, Sun Y, Guo ZZ. Ultrasound molecular imaging and its applications in cancer diagnosis and therapy. ACS Sensors 2022; 7(10): 2857-2864. https://doi.org/10.1021/acssensors.2c01468 DOI: https://doi.org/10.1021/acssensors.2c01468
Jones OT, Matin RN, Van der Schaar M, Bhayankaram KP, Ranmuthu CK, Islam MS, Walter FM. Artificial intelligence and machine learning algorithms for early detection of skin cancer in community and primary care settings: A systematic review. The Lancet Digital Health 2022; 4(6): 466-476. https://doi.org/10.1016/S2589-7500(22)00023-1 DOI: https://doi.org/10.1016/S2589-7500(22)00023-1
López-López Á, López-Gonzálvez Á, Barbas C. Metabolomics for searching validated biomarkers in cancer studies: A decade in review. Expert Review of Molecular Diagnostics 2024; 24(7): 601-626. https://doi.org/10.1080/14737159.2024.2368603 DOI: https://doi.org/10.1080/14737159.2024.2368603
Duffy MJ. Biomarkers for prostate cancer: Prostate-specific antigen and beyond. Clinical Chemistry and Laboratory Medicine (CCLM) 2020; 58(3): 326-339. https://doi.org/10.1515/cclm-2019-0693 DOI: https://doi.org/10.1515/cclm-2019-0693
Ranganath A, Sakalecha AK, Darshan AV, Vineela E. MRI assessment of ovarian masses and correlating with CA-125. Journal of Cancer Research and Therapeutics 2024; 20(3): 869-873. https://doi.org/10.4103/jcrt.jcrt_656_21 DOI: https://doi.org/10.4103/jcrt.jcrt_656_21
Hou S, Jing J, Wang Y, Du L, Tian B, Xu X, Shi Y. Evaluation of clinical diagnostic and prognostic value of preoperative serum carcinoembryonic antigen, CA19-9, and CA24-2 for colorectal cancer. Alternative Therapies in Health & Medicine 2023; 29(6): 192-197. https://pubmed.ncbi.nlm.nih.gov/ 37295009/
Talia KL, Banet N, Buza N. The role of HER2 as a therapeutic biomarker in gynaecological malignancy: Potential for use beyond uterine serous carcinoma. Pathology 2023; 55(1): 8-18. https://doi.org/10.1016/j.pathol.2022.11.004 DOI: https://doi.org/10.1016/j.pathol.2022.11.004
Casolino R, Beer PA, Chakravarty D, Davis MB, Malapelle U, Mazzarella L, Biankin AV. Interpreting and integrating genomic tests results in clinical cancer care: Overview and practical guidance. CA: A Cancer Journal for Clinicians 2024; 74(3): 264-285. https://doi.org/10.3322/caac.21825 DOI: https://doi.org/10.3322/caac.21825
Baidya K, Devi YS, Devi AS, Singh YI, Das D, Mahawar R, Devi NN. Hypofractionated radiotherapy with concurrent chemotherapy with weekly cisplatin in locally advanced relatively radioresistant subsites of head and neck cancers. International Journal of Medicine and Medical Research 2022; 8(2): 24-33. https://doi.org/10.11603/ijmmr.2413-6077.2022.2.13118 DOI: https://doi.org/10.11603/ijmmr.2413-6077.2022.2.13118
Goodman RS, Johnson DB, Balko JM. Corticosteroids and cancer immunotherapy. Clinical Cancer Research 2023; 29(14): 2580-2587. https://doi.org/10.1158/1078-0432.CCR-22-3181 DOI: https://doi.org/10.1158/1078-0432.CCR-22-3181
Huang R, Zhou PK. DNA damage repair: Historical perspectives, mechanistic pathways and clinical translation for targeted cancer therapy. Signal Transduction and Targeted Therapy 2021; 6: article 254. https://doi.org/10.1038/s41392-021-00648-7 DOI: https://doi.org/10.1038/s41392-021-00648-7
Michaelides S, Obeck H, Kechur D, Endres S, Kobold S. Migratory engineering of T cells for cancer therapy. Vaccines 2022; 10(11): article 1845. https://doi.org/10.3390/vaccines10111845 DOI: https://doi.org/10.3390/vaccines10111845
Yin W, Wang J, Jiang L, Kang YJ. Cancer and stem cells. Experimental Biology and Medicine 2021; 246(16): 1791-1801. https://doi.org/10.1177/15353702211005390 DOI: https://doi.org/10.1177/15353702211005390
Alati S, Singh R, Pomper MG, Rowe SP, Banerjee SR. Preclinical development in radiopharmaceutical therapy for prostate cancer. Seminars in Nuclear Medicine 2023; 53(5): 663-686. https://doi.org/10.1053/j.semnuclmed.2023.06.007 DOI: https://doi.org/10.1053/j.semnuclmed.2023.06.007
Rivas Loya R, Jutte PC, Kwee TC, van Ooijen PM. Computer 3D modeling of radiofrequency ablation of atypical cartilaginous tumours in long bones using finite element methods and real patient anatomy. European Radiology Experimental 2022; 6: article 21. https://doi.org/10.1186/s41747-022-00271-3 DOI: https://doi.org/10.1186/s41747-022-00271-3
Bholakant R, Dong B, Zhou X, Huang X, Zhao C, Huang D, Feijen J. Multi-functional polymeric micelles for chemotherapy-based combined cancer therapy. Journal of Materials Chemistry B 2021; 9: 8718-8738. https://doi.org/10.1039/D1TB01771C DOI: https://doi.org/10.1039/D1TB01771C
Custers JA, Davis L, Messiou C, Prins JB, van der Graaf WT. The patient perspective in the era of personalized medicine: What about scanxiety?” Cancer Medicine 2021; 10(9): 2943-2945. https://doi.org/10.1002/cam4.3889 DOI: https://doi.org/10.1002/cam4.3889
Locke FL, Miklos DB, Jacobson CA, Perales MA, Kersten MJ, Oluwole OO, Westin JR. Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma. New England Journal of Medicine 2022; 386(7): 640-654. https://doi.org/10.1056/NEJMoa2116133 DOI: https://doi.org/10.1056/NEJMoa2116133
Li Q, Han J, Yang Y, Chen Y. PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy. Frontiers in Immunology 2022; 13: article 1070961. https://doi.org/10.3389/fimmu.2022.1070961 DOI: https://doi.org/10.3389/fimmu.2022.1070961
Lee A. MYL-1402O: A bevacizumab biosimilar. Targeted Oncology 2022; 17(1): 85-88. https://doi.org/10.1007/s11523-021-00858-7 DOI: https://doi.org/10.1007/s11523-021-00858-7
Hazra A, Bose P, Sunita S, Pattanayak SP. Molecular epigenetic dynamics in breast carcinogenesis. Archives of Pharmacal Research 2021; 44(8): 741-763. https://doi.org/10.1007/s12272-021-01348-0 DOI: https://doi.org/10.1007/s12272-021-01348-0
Koylu B, Tekin F, Aktas BY, Kilickap S, Koksal D. Pazopanib-induced chylothorax in a patient with renal cell carcinoma. Anti-Cancer Drugs 2022; 33(1): 555-557. https://doi.org/10.1097/CAD.0000000000001172 DOI: https://doi.org/10.1097/CAD.0000000000001172
Titze-de-Almeida SS, Brandão PR, Faber I, Titze-de-Almeida R. Leading RNA interference therapeutics part 1: Silencing hereditary transthyretin amyloidosis, with a focus on patisiran. Molecular Diagnosis & Therapy 2020; 24(1): 49-59. https://doi.org/10.1007/s40291-019-00434-w DOI: https://doi.org/10.1007/s40291-019-00434-w
Sutherland JM. Health services research and government’s spending on healthcare programs: A welcome misalignment?” Healthcare Policy 2020; 16(2): 6-13. https://doi.org/10.12927/hcpol.2020.26358 DOI: https://doi.org/10.12927/hcpol.2020.26358
Yuce TK, Chung JW, Barnard C, Bilimoria KY. Association of state certificate of need regulation with procedural volume, market share, and outcomes among Medicare beneficiaries. JAMA 2020; 324(20): 2058-2068. https://doi.org/10.1001/jama.2020.21115 DOI: https://doi.org/10.1001/jama.2020.21115
Straccamore M, Loreto V, Gravino P. The geography of technological innovation dynamics. Scientific Reports 2023; 13: article 21043. https://doi.org/10.1038/s41598-023-48342-8 DOI: https://doi.org/10.1038/s41598-023-48342-8
Dyba T, Randi G, Bray F, Martos C, Giusti F, Nicholson N, Gavin A, Flego M, Neamtiu L, Dimitrova N, Carvalho RN, Ferlay J, Bettio M. The European cancer burden in 2020: Incidence and mortality estimates for 40 countries and 25 major cancers. European Journal of Cancer 2021; 157: 308-347. https://doi.org/10.1016/j.ejca.2021.07.039 DOI: https://doi.org/10.1016/j.ejca.2021.07.039
Horgan D, Mia R, Erhabor T, Hamdi Y, Dandara C, Lal JA, Domgue JF, Ewumi O, Nyawira T, Meyer S, Kondji D, Francisco NM, Ikeda S, Chuah C, De Guzman R, Paul A, Nallamalla KR, Park WY, Tripathi V, Tripathi R, Johns A, Singh MP, Whittaker K, Dube F, Mukherji D, Abu Rasheed HM, Kozaric M, Pinto JA, Stefani SD, Augustovski F, Rueda M, Alarcon RF, Barrera-Saldana HA. Fighting cancer around the world: A framework for action. Healthcare 2022; 10(11): article 2125. https://doi.org/10.3390/healthcare10112125 DOI: https://doi.org/10.3390/healthcare10112125
World Health Organization. Towards a healthier Kyrgyz Republic: Progress report 2020 on health and sustainable development. 2020. https://iris.who.int/handle/10665/338569.
Komilova NK. Territorial analysis of medical geographical conditions of Uzbekistan. Current Research in Behavioral Sciences 2021; 2: article 100022. https://doi.org/10.1016/j.crbeha.2021.100022 DOI: https://doi.org/10.1016/j.crbeha.2021.100022
Fahrmann JF, Schmidt CM, Mao X, Irajizad E, Loftus M, Zhang J, Patel N, Vykoukal J, Dennison JB, Long JP, Do KA, Zhang J, Chabot JA, Kluger MD, Kastrinos F, Brais L, Babic A, Jajoo K, Lee LS, Clancy TE, Ng K, Bullock A, Genkinger J, Yip-Schneider MT, Maitra A, Wolpin BM, Hanash S. Lead-time trajectory of CA19-9 as an anchor marker for pancreatic cancer early detection. Gastroenterology 2021; 160(4): 1373-1383. https://doi.org/10.1053/j.gastro.2020.11.052 DOI: https://doi.org/10.1053/j.gastro.2020.11.052
Wang FH, Wei XL, Feng J, Li Q, Xu N, Hu XC, Liao W, Jiang Y, Lin XY, Zhang QY, Yuan XL, Huang HX, Chen Y, Dai GH, Shi JH, Shen L, Yang SJ, Shu YQ, Liu YP, Wang W, Wu H, Feng H, Yao S, Xu RH. Efficacy, safety, and correlative biomarkers of toripalimab in previously treated recurrent or metastatic nasopharyngeal carcinoma: A phase II clinical trial (POLARIS-02). Journal of Clinical Oncology 2021; 39(7): 704-712. https://doi.org/10.1200/JCO.20.02712 DOI: https://doi.org/10.1200/JCO.20.02712
Hussen NH, Hasan AH, FaqiKhedr YM, Bogoyavlenskiy A, Bhat AR, Jamalis J. Carbon Dot Based Carbon Nanoparticles as Potent Antimicrobial, Antiviral, and Anticancer Agents. ACS Omega 2024; 9(9): 9849-9864. https://doi.org/10.1021/acsomega.3c05537 DOI: https://doi.org/10.1021/acsomega.3c05537
Polatova DSh, Madaminov AYu. Molecular and clinical aspects of oropharyngeal squamous cell carcinoma associated with human Papillomavirus. Opuholi Golovy i Sei 2021; 11(2): 31-40. https://doi.org/10.17650/2313-805X-2021-11-2-31-40 DOI: https://doi.org/10.17650/2313-805X-2021-11-2-31-40
Polatova DSh, Madaminov AYu, Savkin AV, Nurzhabov AI, Asamedinov NK, Ibragimova DA, Davletov RR, Nasirov SK. PD-L1 and p53 expression in squamous cell carcinoma of the oropharynx depending on human papilloma virus status. Opuholi Golovy i Sei 2023; 13(2): 44-56. https://doi.org/10.17650/2222-1468-2023-13-2-44-56 DOI: https://doi.org/10.17650/2222-1468-2023-13-2-44-56
Terefe EM, Opulencia MJC, Rakhshani A, Ansari MJ, Sergeevna SE, Awadh SA, Polatova DSh, Abdulkadhim AH, Mustafa YF, Kzar HH, Al-Gazally ME, Kadhim MM, Taherian G. Roles of CCR10/CCL27-CCL28 axis in tumour development: mechanisms, diagnostic and therapeutic approaches, and perspectives. Expert Reviews in Molecular Medicine 2022; 24: article e37. https://doi.org/10.1017/erm.2022.28 DOI: https://doi.org/10.1017/erm.2022.28
Fredsøe J, Koetsenruyter J, Vedsted P, Kirkegaard P, Vaeth M, Edwards A, Ørntoft TF, Sørensen KD, Bro F. The effect of assessing genetic risk of prostate cancer on the use of PSA tests in primary care: A cluster randomized controlled trial. PLOS Medicine 2020; 17(2): article e1003033. https://doi.org/10.1371/journal.pmed.1003033 DOI: https://doi.org/10.1371/journal.pmed.1003033
Chen Y, Zhang J, Chen Q, Li T, Chen K, Yu Q, Lin X. Three-dimensional printing technology for localised thoracoscopic segmental resection for lung cancer: A quasi-randomised clinical trial. World Journal of Surgical Oncology 2020; 18: article 223. https://doi.org/10.1186/s12957-020-01998-2 DOI: https://doi.org/10.1186/s12957-020-01998-2
Komilova N, Egamkulov K, Hamroyev M, Khalilova K, Zaynutdinova D. The impact of urban air pollution on human health. Medicni Perspektivi 2023; 28(3): 170-179. https://doi.org/10.26641/2307-0404.2023.3.289221 DOI: https://doi.org/10.26641/2307-0404.2023.3.289221
Komilova N, Karshibaeva L, Egamberdiyeva U, Egamkulov K. Territorial Analysis of the Nosoecological Situation and the Health of the Population of the Syrdarya Region. Universal Journal of Public Health 2024; 12(2): 207-217. https://doi.org/10.13189/ujph.2024.120204 DOI: https://doi.org/10.13189/ujph.2024.120204
Latka K, Kolodziej W, Pawlak K, Sobolewski T, Rajski R, Chowaniec J, Olbrycht T, Tanaka M, Latka D. Fully Endoscopic Spine Separation Surgery in Metastatic Disease—Case Series, Technical Notes, and Preliminary Findings. Medicina (Lithuania) 2023; 59(5): article 993. https://doi.org/10.3390/medicina59050993 DOI: https://doi.org/10.3390/medicina59050993
Ravshanov AX, Suhail M, Komilova N, Ravshanov S. Medical geographical zoning in part of Uzbekistan - A regional synthesis. Regional Science Policy and Practice 2024; 16(12): article 100142. https://doi.org/10.1016/j.rspp.2024.100142 DOI: https://doi.org/10.1016/j.rspp.2024.100142
Rojas LA, Sethna Z, Soares KC, Olcese C, Pang N, Patterson E, Lihm J, Ceglia N, Guasp P, Chu A, Chandra AK, Waters T, Ruan J, Amisaki M, Zebboudj A, Odgerel Z, Payne G, Derhovanessian E, Müller F, Rhee I, Yadav M, Dobrin A, Sadelain A, Łuksza M, Cohen N, Tang L, Basturk O, Gönen M, Katz S, Do RK, Epstein ES, Momtaz P, Park W, Sugarman R, Varghese AM, Won E, Desai A, Wei AC, D’Angelica MI, Kingham TP, Mellman I, Merghoub T, Wolchok JD, Sahin U, Türeci Ö, Greenbaum BD, Jarnagin WR, Drebin J, O’Reilly EM, Balachandran VP. Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. Nature 2023; 618(7963): 144-150. https://doi.org/10.1038/s41586-023-06063-y DOI: https://doi.org/10.1038/s41586-023-06063-y
Мамонтов IМ, Tamm ТІ, Kramarenko КО, Ryabushchenko DD, Sytnik DA, Nepomniashchyi VV, Bardiuk OYa. Endoscopic retrograde cholangiopancreatography and endoscopic decompression in the malignant obstruction of the extrahepatic biliary tracts - a retrospective analysis. Ukrainian Journal of Radiology and Oncology 2023; 31(1): 28-37. https://doi.org/10.46879/ukroj.1.2023.28-37 DOI: https://doi.org/10.46879/ukroj.1.2023.28-37
Mamontov IM, Tamm TI, Kramarenko KO, Rjabushhenko DD, Sytnik DA, Nepomniashchyi VV. Risk factors for post-endoscopic retrograde pancreatography pancreatitis in malignant extrahepatic biliary obstruction: a retrospective single-center study. Ukrainian Journal of Radiology and Oncology 2023; 31(2): 150-160. https://doi.org/10.46879/ukroj.2.2023.150-160 DOI: https://doi.org/10.46879/ukroj.2.2023.150-160
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
